 Toshimasa Clark
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 252 | 1.390 |
Why?
| | Radiology Information Systems | 3 | 2019 | 28 | 1.190 |
Why?
| | Contrast Media | 4 | 2019 | 394 | 1.140 |
Why?
| | Thyroid Nodule | 2 | 2019 | 56 | 1.100 |
Why?
| | Radiology | 3 | 2017 | 159 | 1.010 |
Why?
| | Magnetic Resonance Angiography | 2 | 2019 | 234 | 0.990 |
Why?
| | Algorithms | 5 | 2019 | 1617 | 0.950 |
Why?
| | Decision Support Systems, Clinical | 2 | 2017 | 206 | 0.850 |
Why?
| | Incidental Findings | 3 | 2019 | 80 | 0.770 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1514 | 0.750 |
Why?
| | Tomography, X-Ray Computed | 3 | 2016 | 2511 | 0.680 |
Why?
| | Meglumine | 1 | 2019 | 14 | 0.630 |
Why?
| | Adrenocortical Adenoma | 1 | 2019 | 1 | 0.630 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 33 | 0.610 |
Why?
| | Organometallic Compounds | 1 | 2019 | 106 | 0.580 |
Why?
| | Image Enhancement | 1 | 2019 | 168 | 0.580 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2019 | 83 | 0.570 |
Why?
| | Sensitivity and Specificity | 6 | 2019 | 1847 | 0.550 |
Why?
| | Radiation Protection | 1 | 2017 | 38 | 0.540 |
Why?
| | Programming Languages | 1 | 2016 | 23 | 0.520 |
Why?
| | Radiography, Interventional | 1 | 2017 | 105 | 0.520 |
Why?
| | Ultrasonography | 2 | 2019 | 713 | 0.510 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 115 | 0.510 |
Why?
| | Radiologists | 1 | 2016 | 41 | 0.510 |
Why?
| | Data Mining | 1 | 2017 | 110 | 0.500 |
Why?
| | Gadolinium | 1 | 2016 | 78 | 0.500 |
Why?
| | Radiation Dosage | 1 | 2017 | 154 | 0.500 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2015 | 18 | 0.490 |
Why?
| | Models, Cardiovascular | 1 | 2016 | 192 | 0.470 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 99 | 0.470 |
Why?
| | Guideline Adherence | 2 | 2016 | 527 | 0.460 |
Why?
| | Blood Flow Velocity | 1 | 2016 | 406 | 0.460 |
Why?
| | Computer Simulation | 2 | 2016 | 941 | 0.450 |
Why?
| | Arteries | 1 | 2016 | 266 | 0.450 |
Why?
| | Mobile Applications | 1 | 2016 | 166 | 0.430 |
Why?
| | Medical Records Systems, Computerized | 1 | 2014 | 93 | 0.420 |
Why?
| | User-Computer Interface | 1 | 2014 | 149 | 0.410 |
Why?
| | Thyroid Neoplasms | 1 | 2016 | 311 | 0.390 |
Why?
| | Documentation | 1 | 2014 | 185 | 0.380 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 739 | 0.370 |
Why?
| | Neoplasms | 2 | 2016 | 2454 | 0.370 |
Why?
| | Quality Improvement | 2 | 2017 | 1112 | 0.370 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 371 | 0.360 |
Why?
| | Splenic Diseases | 1 | 2011 | 5 | 0.360 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3089 | 0.330 |
Why?
| | Prostatic Neoplasms | 1 | 2017 | 999 | 0.320 |
Why?
| | Abdominal Injuries | 1 | 2011 | 118 | 0.320 |
Why?
| | Software | 1 | 2014 | 608 | 0.310 |
Why?
| | Spleen | 1 | 2011 | 508 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1274 | 0.300 |
Why?
| | Thyroid Gland | 2 | 2019 | 95 | 0.280 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 1920 | 0.250 |
Why?
| | Software Validation | 2 | 2016 | 9 | 0.240 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3397 | 0.240 |
Why?
| | Middle Aged | 9 | 2024 | 31177 | 0.230 |
Why?
| | Humans | 18 | 2024 | 129847 | 0.200 |
Why?
| | Liver Neoplasms | 2 | 2019 | 636 | 0.190 |
Why?
| | Pancreatectomy | 1 | 2024 | 242 | 0.190 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 379 | 0.190 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2024 | 269 | 0.180 |
Why?
| | Male | 10 | 2024 | 63759 | 0.180 |
Why?
| | Body Composition | 1 | 2024 | 649 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2024 | 14553 | 0.160 |
Why?
| | Female | 11 | 2024 | 68829 | 0.160 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 60 | 0.150 |
Why?
| | Risk Assessment | 2 | 2019 | 3269 | 0.150 |
Why?
| | Injections, Intravenous | 1 | 2019 | 202 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 63 | 0.150 |
Why?
| | Artifacts | 1 | 2019 | 127 | 0.150 |
Why?
| | Pancreatic Pseudocyst | 1 | 2018 | 13 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 232 | 0.140 |
Why?
| | Aneurysm, False | 1 | 2018 | 47 | 0.140 |
Why?
| | Famous Persons | 1 | 2017 | 7 | 0.140 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 270 | 0.140 |
Why?
| | Drainage | 1 | 2018 | 164 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 879 | 0.130 |
Why?
| | Observer Variation | 1 | 2017 | 314 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2017 | 283 | 0.130 |
Why?
| | Prospective Studies | 2 | 2019 | 7158 | 0.130 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 134 | 0.130 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 627 | 0.120 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2015 | 20 | 0.120 |
Why?
| | Phantoms, Imaging | 1 | 2016 | 137 | 0.120 |
Why?
| | Societies, Medical | 1 | 2019 | 759 | 0.120 |
Why?
| | Pattern Recognition, Automated | 1 | 2015 | 75 | 0.120 |
Why?
| | Antibodies, Antinuclear | 1 | 2015 | 66 | 0.120 |
Why?
| | Heart Block | 1 | 2015 | 40 | 0.120 |
Why?
| | Sjogren's Syndrome | 1 | 2015 | 49 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 756 | 0.110 |
Why?
| | Aged | 5 | 2024 | 22107 | 0.110 |
Why?
| | Microcomputers | 1 | 2014 | 15 | 0.110 |
Why?
| | Software Design | 1 | 2014 | 23 | 0.110 |
Why?
| | United States | 3 | 2016 | 13913 | 0.110 |
Why?
| | Stents | 1 | 2018 | 504 | 0.110 |
Why?
| | Biopsy | 1 | 2017 | 1089 | 0.110 |
Why?
| | Hemorrhage | 1 | 2018 | 680 | 0.100 |
Why?
| | Information Storage and Retrieval | 1 | 2014 | 108 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2017 | 639 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2016 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1434 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2015 | 494 | 0.080 |
Why?
| | Adult | 5 | 2019 | 35634 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2017 | 979 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2020 | 4077 | 0.080 |
Why?
| | Prevalence | 1 | 2016 | 2564 | 0.080 |
Why?
| | Anthropometry | 1 | 2024 | 204 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2344 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2024 | 594 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1872 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 680 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 931 | 0.040 |
Why?
| | Plastics | 1 | 2018 | 47 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 204 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 181 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7066 | 0.030 |
Why?
| | Metals | 1 | 2018 | 123 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 808 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1248 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 10241 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 3773 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1560 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 596 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 4896 | 0.030 |
Why?
| | Fetal Diseases | 1 | 2015 | 164 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 2015 | 276 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2378 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2646 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2489 | 0.020 |
Why?
| | Infant | 1 | 2018 | 9018 | 0.010 |
Why?
| | Child, Preschool | 1 | 2018 | 10522 | 0.010 |
Why?
| | Mice | 1 | 2020 | 16983 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 6423 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 12467 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 20451 | 0.010 |
Why?
| | Child | 1 | 2018 | 20962 | 0.010 |
Why?
| | Animals | 1 | 2020 | 35409 | 0.010 |
Why?
|
|
Clark's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|